It’s nearly impossible to list all the ways in which stem
cell exploration is important because the usefulness of these cells is
virtually limitless. Stem cells have the potential to treat a huge range of
diseases and conditions that millions of people around the world suffer from.
Their ability to treat so many diseases rests on their unique properties of
self-renewal, differentiation and their unspecialized nature.
Fate Therapeutics (NASDAQ: FATE), San Diego, California, is
a clinical-stage biopharmaceutical company with a focus on the discovery and
development of pharmacologic modulators of adult stem cells to treat severe,
life-threatening diseases. It is widely known that adult stem cells play a key
role in the growth, maintenance and repair of many tissues and organ systems in
the body. As a result of their natural ability to self-renew, and to regenerate
and repair diseased or damaged tissue, adult stem cells possess exciting
prospects for a myriad of promising applications.
FATE uses the proven pharmacologic modalities of small
molecules and targets well-characterized biological mechanisms to program the
fate and enhance the therapeutic potential of adult stem cells. The company’s
primary product candidate, PROHEMA®, is an ex vivo programmed hematopoietic
cellular therapeutic. Today, PROHEMA is in clinical development for patients
undergoing hematopoietic stem cell transplantation for the treatment of
hematologic malignancies and certain rare genetic disorders. Integral to the
company’s focus is the application of its reprogramming modulators to develop
human induced pluripotent stem cell-derived cellular therapeutics, and
evaluating the in vivo programming of muscle satellite stem cells using its
Wnt7a-based protein analogs for muscle regeneration.
The company’s therapeutic programs target innovative
mechanisms and are designed to seek out diseases with high degrees of unmet
clinical need. As a result of this focus, FATE realizes that it can benefit by
working with other companies who bring new ideas and experiences to the drug
development market. For this reason, FATE is open to collaborating with
potential partners who share its values and drive to advance stem cell science
and move closer to developing therapeutics that will ultimately deliver much needed
health benefits to those who need them most.
For more information on the company, visit
www.fatetherapeutics.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
